People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Other Health Care, Other, Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Remedi SeniorCare Holding Corp | — | Other Health Care | Series D+ | $342.2M | $3.4B | 2011 |
| Thorley Industries Llc | — | Other | Series B | $118.6M | $219.1M | 2014 |
| Lemnature AquaFarms Corp | — | Other | Series B | $58.5M | $64.8M | 2021 |
| PlanetRisk, Inc. | — | Other Technology | Series A | $29.4M | $41.6M | 2016 |
| PlayerLync Holdings, Inc. | — | Other Technology | Series A | $26.7M | $345.4M | 2013 |
| Keraplast Technologies, LLC | — | Biotechnology | Seed | $6.3M | $111.0M | — |
| Keraplast Technologies Management, LLC | — | Biotechnology | Seed | $2.4M | $3.8M | — |
| HealthTeacher, Inc. | — | Other Health Care | Seed | $1.7M | $27.0M | 2009 |
| APFusion, Inc. | — | Other Technology | Pre-Seed | $500K | $9.8M | 2021 |
Robert A Smith at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert A Smith on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Espensen | 2 | 3 |
| William F. Shea | 2 | 2 |
| Norman P. Blake | 2 | 2 |
| Greg A. Kozmetsky | 2 | 2 |
| Tim Herring | 2 | 2 |
| Robert Smith | 1 | 17 |
| Koleman Karleski | 1 | 5 |
| Andrew Lindner | 1 | 5 |
| Alex Smith | 1 | 5 |
| Robert Edwards | 1 | 5 |
| PAUL BARTLETT | 1 | 4 |
| William Shea | 1 | 4 |
| Eric Becker | 1 | 4 |
| Michael Mahon | 1 | 3 |
| Jared S. Hendricks | 1 | 3 |
| Casey West | 1 | 3 |
| Michael Bronfein | 1 | 2 |
| Frank Jimenez | 1 | 2 |
| Theodore Dacko | 1 | 2 |
| William W. Bishop | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.